Drug Trial Radar · NCT06445075
Efficacy and Safety of Apitegromab for the Treatment of Adults Who Are Overweight or Obese
Last checked: Nov 20, 2026Latest source record: Jan 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
102
Actual
Start
May 21, 2024
Primary completion
Mar 4, 2025
Study completion Jun 17, 2025
Sponsor
- Lead sponsor
- Scholar Rock, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jun 6, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
A phase 2 study to evaluate the effects of apitegromab as an adjunctive therapy to GLP-1 receptor agonist therapy in subjects with overweight or obesity
Conditions
- Overweight and Obesity
Interventions
ApitegromabDrug
Apitegromab (SRK-015) is a fully human anti-proMyostatin monoclonal antibody (mAb) that specifically binds to human pro/latent myostatin, inhibiting myostatin activation. Apitegromab was administered every 4 weeks by intravenous (IV) infusion.
PlaceboDrug
Same appearance and composition as apitegromab drug product but does not contain the active ingredient. Placebo was administered every 4 weeks by intravenous (IV) infusion.
TirzepatideDrug
Glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist. Tirzepatide was administered every week by subcutaneous injection.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from Baseline in total Lean Body Mass (kg) at 24 weeksTime frame: Baseline and 24 weeks
Locations
7 sites in 1 country. Site status is shown where the registry gives one.
ProSciento CRU
Chula Vista, California
AdventHealth Translational Research Institute
Orlando, Florida
Great Lakes Clinical Trials, LLC d/b/a Flourish Research
Chicago, Illinois
Tandem Clinical Research GI, LLC
Marrero, Louisiana
Alliance for Multispecialty Research, LLC
Norman, Oklahoma
Apex Mobile Clinical Research
Bellaire, Texas
Clinical Trials of Texas, LLC dba Flourish Research
San Antonio, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.